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Clostridiumdifficile toxin A is known to cause actin disaggre-
gation through the enzymatic inactivation of intracellular Rho
proteins. Based on the rapid and severe cell rounding of toxin
A-exposed cells, we speculated that toxin A may be involved in
post-translational modification of tubulin, leading to microtu-
bule instability. In the current study, we observed that toxin A
strongly reduced -tubulin acetylation in human colonocytes
and mouse intestine. Fractionation analysis demonstrated that
toxin A-induced -tubulin deacetylation yielded monomeric
tubulin, indicating the presence of microtubule depolymeriza-
tion. Inhibition of the glucosyltransferase activity against Rho
proteins of toxin A by UDP-2,3-dialdehyde significantly abro-
gated toxin A-induced -tubulin deacetylation. In colonocytes
treated with trichostatin A (TSA), an inhibitor of the HDAC6
tubulin deacetylase, toxin A-induced -tubulin deacetylation
and loss of tight junction were completely blocked. Administra-
tion of TSA also attenuated proinflammatory cytokine produc-
tion, mucosal damage, and epithelial cell apoptosis in mouse
intestine exposed to toxin A. These results suggest that toxin A
causes microtubule depolymerization by activation of HDAC6-
mediated tubulin deacetylation. Indeed, blockage of HDAC6 by
TSA markedly attenuates -tubulin deacetylation, proinflam-
matory cytokine production, and mucosal damage in a toxin
A-induced mouse enteritis model. Tubulin deacetylation is an
important component of the intestinal inflammatory cascade
following toxinA-mediatedRho inactivation in vitro and in vivo.
Clostridium difficile is the causative pathogen of antibiotic-
associated diarrhea and pseudomembranous colitis in humans
and animals with a 10% symptomatic infection rate among hos-
pitalized patients (1). Two toxins, A and B, released fromC. dif-
ficile, are responsible for the massive fluid secretion, apoptosis
of surface colonocytes, and acute enteritis seen during infec-
tion. The two exotoxins, which share63% amino acid homol-
ogy, have glucosyltransferase activity (2–4) that inactivates Rho
family proteins, leading to actin disaggregation (5, 6).Monoglu-
cosylation of Rho, Rac, and Cdc42 by toxin A at threonine 37
prevents Rho family proteins from participating in the forma-
tion of actin filaments (7). This mechanism is believed to be a
main cause for the cell rounding that is characteristic of toxin-
exposed cells (6, 8). However, despite the presence of a rapid
and severe change in the shape of infected cells, the effect of
toxinAon the post-translationalmodification of tubulin and its
subsequent influence on microtubule instability have not
received detailed attention.
Microtubule instability is critical to cell shape (9), cell move-
ment (10), intracellular transport of organelles (11), and the
separation of chromosomes duringmitosis (12). This instability
results in the continual and rapid turnover ofmicrotubules, in a
process that is crucial for cytoskeletal remodeling (9–11).
Because microtubules play a pivotal role in mitosis, drugs that
influence microtubule polymerization have been used to
study the mechanisms of cytoskeletal organization (13). For
example, colchicine (14) is known to inhibit the microtubule
polymerization that leads to mitosis, whereas taxol (15) sta-
bilizes microtubules and blocks cell division. The instability
of microtubules, which are composed of -tubulin and -tu-
bulin (16), has also been associated with post-translational
modifications of tubulin, such as tyrosination and acetylation.
In particular, acetylation of -tubulin at Lys-40 has been
reported to enhance microtubule polymerization (17). Al-
though the precise acetyltransferase for tubulin is not yet
known, HDAC6 has been implicated in the deacetylation of
tubulin (18–20).
The nine known isoforms of mammalian HDAC can be clas-
sified into two groups based on amino acid sequence length and
the degree of sequence homology to a single prototypic yeast
HDACs. The smaller class I HDACs (400–500 amino acids)
include HDAC1, HDAC2, HDAC3, and HDAC8 (21). The
larger class II HDACs (1,000 amino acids) include HDAC4,
HDAC5 (22), HDAC6, and HDAC7 (23), and HDAC9. Most
class I and class II HDACs are located in the nucleus except
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class II HDAC6, which is localized strictly to the cytosol (20,
24–26). Based on the hypothesis that abnormal microtubule
depolymerization would probably result in barrier dysfunction
of epithelial cells, we studied the possible effects of HDAC6-
mediated tubulin deacetylation on inflammation and epithelial
damage induced by C. difficile toxin A. Our results indicate a
major effect of toxin A on microtubules in vitro and in vivo
mediated by deacetylation of tubulin.
EXPERIMENTAL PROCEDURES
ToxinA Preparation andCell Culture—ToxinAwas purified
fromC. difficile strain VPI 10463 (American Type Culture Col-
lection, Manassas, VA) as described previously (27). The purity
of native toxin A was assessed by gel electrophoresis, which
confirmed a single protein at the expected molecular mass of
307 kDa (28). HT29 and CaCo2 cells derived from human colo-
rectal adenocarcinoma were maintained in McCoy’s 5A me-
dium (Invitrogen) and DMEM (Invitrogen), respectively. Cells
were cultured in a 37 °C humidified incubator with 5% CO2.
Antibodies and Reagents—Polyclonal antibodies against tu-
bulin, acetylated tubulin, and HDAC6 were obtained from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). UDP-23-
dialdehyde, N-acetyl-L-cysteine (NAC),3 hydrogen peroxide
(H2O2), sodium formate, trichostatin A, trapoxin, sodium
butyrate, colchicine, and the antibody against-actinwere pur-
chased from Sigma. The polyclonal antibody against caspase-3
was obtained from Cell Signaling Technology (Beverly, MA).
Immunoblot Analysis—Human colonocytes were washed
with cold phosphate-buffered saline (PBS) and lysed in buffer
(150 mMNaCl, 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 1% Non-
idet P-40), and equal amounts of protein were fractionated by
SDS-PAGE. The appropriate antibodies were applied, and anti-
gen-antibody complexes were detected with the LumiGlo rea-
gent (New England Biolabs).
Fractionation of Monomeric and Polymeric Tubulin—HT29
human colonocytes were exposed to toxin A for 4 or 8 h and
then washed twice with PBS. For fractionation of polymerized
(polymeric) and depolymerized (monomeric) tubulins, the cells
were incubated with 0.3 ml of reaction buffer containing 10
g/ml leupeptin, 10 g/ml aprotinin, 1 mM phenylmethylsul-
fonyl fluoride, 1 mMMgSO4, and 0.1% Triton X-100 for 20 min
at 37 °C. The supernatant contained the monomeric tubulin
fraction, whereas polymeric tubulin was extracted from the
Triton X-100-insoluble fraction by incubation in an SDS lysis
buffer (25 mM Tris, pH 7.4, 0.4 M NaCl, 0.5% SDS) for 10 min at
37 °C. These fractions were subjected to 10% SDS-PAGE, and
blotted membranes were probed with antibodies against -tu-
bulin, acetylated -tubulin, and -actin.
Isolation of Nuclear and Cytosolic Proteins—HT29 cells were
grown to80% confluence and exposed to toxin A or H2O2 for
3 h. After centrifugation at 500  g, the cell pellet was resus-
pended in five volumes of 0.3 M sucrose and 2% Tween 40 in
Buffer A (10 mM HEPES-potassium hydroxide (KOH), pH 7.9,
containing 10 mM KCl, 1.5 mM MgCl2, 0.1 mM EGTA, 0.5 mM
dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride
(PMSF), 2 g/ml leupeptin, and 2 g/ml pepstatin A). After
cells were subjected to freezing, thawing, and gentle homoge-
nization, nuclei were isolated by centrifugation at 3,000 rpm in
Buffer A. Supernatants were collected as the cytosolic fractions,
and the precipitated pellets were lysed in Buffer A for isolation
of the nuclear proteins.
Enzymatic Activity Assay for HDAC6—Because HDAC6 is
mainly present in the cytosol, whereas the other HDAC family
proteins localize to the nucleus, the HDAC activity observed in
cytosolic extracts was compared with that in nuclear extracts.
Activity was measured from colonocyte nuclear and cytosolic
extracts using a fluorescence activity assay kit (Cayman Chem-
ical, AnnArbor,MI). Using immunoprecipitation assay with an
antibody against HDAC6, activity of colonocyte-HDAC6 in the
presence and absence of toxin A was confirmed. Briefly, each
extract (1 g of total protein) or each immunoprecipitant was
incubated at 37 °Cwith 100Macetylated fluorogenic substrate
in HDAC assay buffer. After 30 min, the lysine developer was
added, and the mixture was incubated for another 15 min at
room temperature. Fluorescence wasmeasured using a Spectra
Max M5 fluorescent plate reader (Molecular Devices, Sunny-
vale, CA) with excitation at 360 nm and emission at 460 nm.
Animals—This study was approved by the Animal Care and
Use Committee of Daejin University (Pocheon, Korea). Male
CD1 mice (Daehan Biolink, Daejeon, Korea) weighing 30–35 g
were used; they had free access to food and water and were
acclimated to these conditions for at least 7 days prior to exper-
iments. Mice were anesthetized by intraperitoneal injection of
sodium pentobarbital (50 mg/kg). Ileal loops (2 cm) were pre-
pared and injected with control buffer (PBS), toxin A (3 g),
TSA (10 nM), or toxin A (3 g) plus TSA in a volume of 100 l
of PBS. After 4 h, animals were sacrificed, and ileal loop tissues
were collected. Tubulin deacetylation and caspase-3 activation
were assessed in tissue extracts by immunoblot analysis with
specific antibodies.
Cell Viability—HT29 cells treated with the various agents
were incubated with 3-(4,5-dimethylthiazole-2-yl)-2,5-diphe-
nyltetrazolium bromide dye for 2 h. The solubilization reagent
was added, and the absorbance was determined at 570 nm
(model 3550, Bio-Rad).
Measurement of Mouse IL-6 and TNF-—Toxin A was pre-
viously reported to stimulate production of interleukin-6 (IL-6)
and tumor necrosis factor- (TNF-) from target cells (20, 21).
To evaluate whether this occurred in our mouse model of gut
inflammation, ileal loops of the above described mice were
homogenized (40 s) and centrifuged (11,000  g, 10 min at
4 °C), and supernatants were collected. Mouse IL-6 and TNF-
were measured by ELISA using appropriate kits obtained from
R&D Systems (Minneapolis, MN).
Confocal Scanning Laser Microscopy—For visualization of
microtubule structures, colonocytes were exposed to control
medium or toxin A for 6 h and then fixed in 4% paraformalde-
hyde dissolved in PBS. After being washed with PBS, the cells
were incubated with a polyclonal anti-acetylated -tubulin
antibody or a polyclonal anti--tubulin antibody (diluted
1:500) in PBS containing 0.05% Tween 20 for 6 h at room tem-
perature (29). After three washings, the anti-acetylated tubulin
antibody-treated cells were incubated with FITC-labeled anti-
3 The abbreviations used are: NAC, N-acetyl-L-cysteine; TSA, trichostatin A;
TER, transepithelial resistance; ROS, reactive oxygen species.
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mouse IgG (1:500) for 2 h at room temperature. The anti--
tubulin antibody-treated cells were incubated with Texas Red-
labeled anti-rabbit IgG (1:500). The cells were then mounted
and analyzed using a Bio-Rad MRC 1024 confocal scanning
laser microscope equipped with a krypton/argon mixed gas
laser as a light source. Excitation was carried out using the 480-
or 594-nm lines from the laser.
Measurement of Transepithelial Resistance (TER)—Colono-
cytes (CaCo-2 cells) were cultured onto polycarbonate filters
(Transwells, Costar, Cambridge,MA) and incubated for 5 days,
reaching confluence. After the cells were exposed to toxin A
alone, toxin A plus TSA, or colchicine for 8 h, TER was mea-
sured with a Millicel ERS Voltohmeter (Millipore, Bedford,
MA) (28). The resistance of the supporting membrane and
medium was subtracted from all readings.
Statistical Analysis—The results are presented as mean val-
ues S.E. Data were analyzed using the SIGMA-STAT profes-
sional statistics software program (Jandel Scientific Software,
San Rafael, CA). Analyses of variance with protected t tests
were used for intergroup comparisons.
RESULTS
Toxin A Induces Deacetylation of Tubulin in HumanColono-
cytes (HT29)—We exposedHT29 cells to toxin A for 2, 4, 6, and
8 h and then measured changes in tubulin acetylation, which is
known to influencemicrotubule polymerization (17). As shown
in Fig. 1A, compared with control cells, the basal acetylation
level of tubulin in toxinA-treated cells wasmarkedly reduced at
4 and 8 h post-treatment. The total amounts of -tubulin and
-actin were unchanged in these cells. We then assessed
whether toxin A-induced tubulin deacetylation influenced
microtubule polymerization. HT29 cells were exposed to toxin
A for 0, 4, and 8 h and incubated in cell membrane-permeabi-
lizing buffer for separation of monomeric and polymeric tubu-
lins (30). Toxin A treatment of HT29 cells significantly and
time-dependently increased the amount of tubulin in the
supernatant (super), indicating that most tubulins were mono-
meric (Fig. 1B). In contrast, the amount of tubulin in cell pellets
(containing polymeric tubulins) was markedly reduced follow-
ing toxin A exposure. Consistent with these findings, highly
acetylated tubulins were detected in control cell pellets but not
in pellets from cells exposed to toxin A for 4 h (Fig. 1B). These
results suggest that toxin A-induced deacetylation of tubulin
causes microtubule depolymerization in human colonocytes.
We then assessed whether toxin A increased tubulin deacety-
lation in the gut epithelium of mice. Ileal loops of CD1 mice
were injected with 3 g of toxin A in 100 l of PBS (n  10).
Four hours later, ilealmucosal scrapingswere collected, protein
extracts were subjected to 10% polyacrylamide gel electro-
phoresis, and blotted membranes were probed with an anti-
body against acetylated -tubulin. A marked decrease in -tu-
bulin acetylation was confirmed in ileal mucosa exposed to
toxin A compared with controls (Fig. 1C). Quantitation of the
immunoblot results showed that tubulin acetylation was 3-fold
lower in toxin A-treated mice than in PBS-treated mice (Fig.
1C, lower panel). Collectively, these results indicate that toxinA
causes tubulin deacetylation in both cultured colonocytes and
the mouse intestinal epithelium.
Depolymerization of Microtubules by Toxin A—We next
assessed whether toxin A-induced deacetylation of tubulin re-
sulted in microtubule depolymerization. To do this, we applied
immunofluorescence staining with an antibody against acety-
lated-tubulin, as described under “Experimental Procedures.”
In control human colonocytes, the anti-acetylated -tubulin
antibody clearly revealed typical microtubule shapes in all
stained cells (Fig. 2A, arrowheads), whereas the anti--tubulin
antibody highly detected such shapes in dividing cells that were
in the process of forming amitotic spindle. Exposure of colono-
cytes to toxin A for 6 h substantially diminished the levels of
polymerized microtubules as well as acetylated tubulins com-
pared with that in control cells (Fig. 2B). This finding is consis-
FIGURE 1. ToxinA inhibits tubulin polymerization throughdeacetylation
in HT29 human colonocytes. A, colonocytes were incubated with toxin A
(TxA) (0.5 g/ml) for the indicated times, cell lysates were subjected to 10%
polyacrylamide gel electrophoresis, and blots were probed with antibodies
against acetylated -tubulin, -tubulin, and -actin. The presented results
are representative of three independent experiments. B, polymerized (poly-
meric) and depolymerized (monomeric) tubulins were isolated from colono-
cytes exposed to toxin A for the indicated times (see “Experimental Proce-
dures”). The supernatant (super) was removed as monomeric tubulin, and
polymeric tubulinwas extracted from the pellet. C, ileal loops of anesthetized
CD1mice (n 10mice/group) were closed and injectedwith toxin A (3g of
toxinA, 100l of PBS) or PBSbuffer for 4h. Ileal loopswere removed, and total
protein extracts from the tissues were resolved on polyacrylamide gels and
probed with an antibody against acetylated -tubulin (top). Densitometric
quantitation was performed (bottom). The results shown are representative
of three independent experiments. *, p 0.05 versus PBS-treated mice. Error
bars, S.E.
Tubulin Deacetylation by Toxin A in Gut Inflammation
32890 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 43•OCTOBER 22, 2010
 at ULSAN NATL INST OF SCIENCE & TECH on August 11, 2013http://www.jbc.org/Downloaded from 
tent with the results in Fig. 1 showing that toxin A treatment
caused tubulin deacetylation, leading to increases in mono-
meric tubulin. This suggests that toxin A, in addition to its role
in depolymerizing actin, may also trigger microtubule depoly-
merization and subsequent cytoskeletal disorganization.
Toxin A-induced Deacetylation of Tubulin Is Dependent on
Both the Enzymatic Activity of Toxin A and the Involvement of
DownstreamSignalingMolecules—ToxinA-inducedmonoglu-
cosylation of Rho family proteins at threonine 37 inactivates the
Rho proteins, resulting in actin disaggregation in various cells
(7). Because a recent study showed that Rho-GTPase is involved
in the increased microtubule instability observed in HIV virus-
infected host cells (31), we assessed whether the enzymatic
activity of toxin A was required for toxin A-induced tubulin
deacetylation. For this purpose, we usedUDP-2,3-dialdehyde,
which has been shown to inhibit the enzymatic activity of toxin
A without inducing structural changes (32). HT29 cells were
exposed to UDP-2,3-dialdehyde for 1 h prior to toxin A expo-
sure, and changes in tubulin acetylation were measured. As
shown in Fig. 3A, toxin Amarkedly reduced tubulin acetylation
in control colonocytes, but this effect was significantly blocked
in cells pretreated with UDP-2,3-dialdehyde, which by itself
did not affect the basal levels of tubulin acetylation. Because
toxinAhas been shown to rapidly cause reactive oxygen species
(ROS) generation as an early downstream signal (33), we
assessed whether blockage of ROS production could inhibit
toxin A-induced tubulin deacetylation. Human colonocytes
were exposed for 1 h to NAC, an H2O2 scavenger, or sodium
formate, a hydroxyl radical scavenger, followed by toxinA stim-
ulation for 4 h. Interestingly, NAC but not sodium formate
specifically inhibited tubulin deacetylation in cells exposed to
toxin A (Fig. 3B). Conversely, direct exposure of HT29 cells to
H2O2 increased tubulin deacetylation in a time/dose-depen-
dent manner (Fig. 3C); 500 M H2O2 completely abrogated
acetylation of tubulin within 1 h, and this effect was retained
through 2 h post-treatment, indicating that H2O2, one of the
main ROS produced in toxin A-treated colonocytes (33), was
capable of directly decreasing tubulin acetylation. Together,
these findings suggest that toxin A-induced tubulin deacetyla-
tion requires the enzymatic activity of toxin A against Rho
proteins as well as the generation of ROS, leading to signal
transduction.
HDAC6 (Histone Deacetylase 6) Mediates Toxin A-induced
Tubulin Deacetylation in Colonocytes—Because HDAC6, a
unique cytosolic deacetylase, is known to be involved in tubulin
deacetylation (18, 19, 24), we examined whether toxin A-medi-
ated tubulin deacetylation is associated withHDAC6 activity in
human colonocytes, using the selective HDAC6 inhibitor, TSA
(34). As expected, TSA-treated human colonocytes showed
increased tubulin acetylation compared with control cells
exposed to culture medium (Fig. 4A). The maximum TSA-in-
duced increase in tubulin acetylation was observed at 1 h post-
treatment, and this level was maintained through 6 h post-
treatment (Fig. 4A). In contrast, sodium butyrate (But) and
FIGURE 2. Effects of toxin A-induced tubulin deacetylation on microtu-
bule organization in human colonocytes. A and B, HT29 cells grown on
coverslips were fixed and immunostainedwith anti-acetylated-tubulin and
anti--tubulin. Levels of microtubule organization were visualized by confo-
cal microscopy. Microtubules observed in human colonocytes are indicated
by arrowheads. The results shown are representative of three independent
experiments. B, human colonocyteswere exposed tomedium (con) or toxinA
for 6 h and then immunostained with anti-acetylated -tubulin or anti--
tubulin. Marked microtubule disorganization was observed in toxin A (TxA)-
treated cells.
FIGURE 3. Toxin A enzymatic activity and downstream signaling mole-
cule (H2O2) are involved in toxin A-induced tubulin deacetylation.
A, human colonocytes were exposed to medium (con), toxin A alone, UDP-
2,3-dialdehyde alone (UDP, 1mM) (32), or UDP-2,3-dialdehyde plus toxin A
(TxA) for 4 h. The lysates were resolved on 10% polyacrylamide gels and
probed with antibodies against acetylated -tubulin and -actin. B, colono-
cytes were exposed to NAC (20 mM) (33), toxin A, toxin A plus NAC, sodium
formate (Formate; 1 mM), and sodium formate plus toxin A for 4 h. The results
shown are representative of three separate experiments.C, colonocyteswere
treated with H2O2 (100–500 M) for the indicated times, and the levels of
tubulin deacetylation were measured.
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trapoxin (TPX), broad spectrum chemical inhibitors of all
HDACs except HDAC6 (34), did not affect the basal level of
tubulin acetylation in human colonocytes (Fig. 4A), suggesting
that HDAC6 is the deacetylase for tubulin in human colono-
cytes. Interestingly, preincubation of colonocytes with TSA for
1 h completely inhibited the deacetylation of tubulin in
response to toxin A, whereas sodium butyrate and trapoxin did
not affect toxin A-induced tubulin deacetylation (Fig. 4B).
Immunostaining and confocal microscopy also revealed that
the marked tubulin deacetylation induced by toxin A was
blocked in TSA-pretreated cells, whereas sodium butyrate
and trapoxin did not inhibit toxin A-induced tubulin
deacetylation (Fig. 4C). TSA alone stimulated a marked
increase in microtubule polymerization compared with
medium control. Using a 3-[4,5-dimethylthiazole-2-yl]-2,5-
diphenyltetrazolium bromide assay to measure changes on cell
viability, we next assessed whether the TSA-induced blockade
of tubulin deacetylation could inhibit the marked drop in cell
viability observed following toxinA treatment. As shown in Fig.
4D, treatment of TSA but not trapoxin significantly blocked the
toxin A-induced reduction of cell viability. TSA alone did not
appear to have any effect on colonocyte viability (Fig. 4D).
Given that HDAC6 appears to be largely responsible for the
increased tubulin deacetylation in colonocytes exposed to toxin
A, and HDAC6 is unique among the deacetylases in being
restricted to the cytosol, we investigated whether toxin A could
activate HDAC6 in colonocytes. Cells were incubated with
toxin A or H2O2 for 3 h, and cytosolic extracts taken as repre-
FIGURE 4. Toxin A causes tubulin deacetylation by activating HDAC6 in human colonocytes. A, colonocytes (HT29) were treated withmedium (con), TSA
(1M), sodium butyrate (But) (1 mM), or trapoxin (TPX) (10 nM) for the indicated times. Cell lysates were resolved on 10% polyacrylamide gels and probedwith
antibodies against acetylated-tubulin and-actin. The results shownare representative of three separate experiments. B, cellswere incubatedwithmedium,
TSA, sodium butyrate, trapoxin, toxin A alone (TxA), or toxin A plus either TSA, But, or trapoxin for 4 h. C, HT29 cells were grown on coverslips, and levels of
microtubule organization were visualized by confocal microscopy and immunostaining with an antibody against acetylated -tubulin. D, HT29 cells were
incubated with medium (con), toxin A, trapoxin or TSA alone, or toxin A plus either trapoxin or TSA. After incubation for 48 h, cell viability was measured by a
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide assay and expressed as a percentage of the results from untreated controls. All reactions were
performed in duplicate, and the results shown represent three independent experiments. *, p  0.001 versus toxin A-stimulated cells. E, toxin A and H2O2
increase HDAC6 activity in colonocytes. HT29 cells were incubated withmedium (con), toxin A (0.5g/ml), or H2O2 (500M) for 3 h, and nuclear and cytosolic
extracts were isolated. The purity of subcellular fractionationwas confirmed by immunoblot analysis with an-actin antibody (C, medium; T, toxin A;H, H2O2).
Activity of HDAC6 was measured as described under “Experimental Procedures.” All reactions were performed in duplicate, and the results shown represent
three independent experiments. *, p 0.005 versus non-stimulated cells. F, HT29 cells were pretreated with TSA (1 M) for 1 h and then exposed to medium
(con), toxin A, or H2O2 for 3 h. HDAC6 in colonocytes was immunoprecipitated by an HDAC6 antibody, and activity of HDAC6 in the immune complexes was
measured. *, p 0.005 versus toxin A-treated cells; #, p 0.001 versusH2O2-treated cells. G, colonocytes (CaCo-2) were treated with TSA (1M) for 1 h prior to
toxin A exposure. TER was determined as described under “Experimental Procedures.” Typical absolute resistance values were 300–350 ohms/cm2. The bars
represent the mean S.E. of three experiments performed in triplicate; *, p 0.001 versus toxin A-stimulated cells. Error bars, S.E.
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senting HDAC6 activity and nuclear extracts taken as repre-
senting the activity of the other HDACs were isolated, incu-
bated with an acetylated fluorogenic substrate, and developed
for visualization of results. As shown in Fig. 4E, the enzymatic
activity of cytosolic HDAC6 was significantly increased by
toxin A or H2O2 stimulation, compared with the medium-
treated control. In contrast, the basal activity of the nuclear
HDACs was relatively higher than that in the cytosol, but toxin
A and H2O2 exposure decreased nuclear HDAC activity (Fig.
4E). The purity of subcellular fractionation was confirmed by
immunoblot analysis with an -actin antibody (C, medium; T,
toxin AH, H2O2). Immunoprecipitation assay with an antibody
against HDAC6 also revealed that activities of HDAC6 isolated
from colonocytes exposed to toxin A or H2O2 were markedly
increased compared with the medium-treated cells. Moreover,
these increases were significantly inhibited by pretreatment of
TSA, suggesting that exposure of colonocytes to toxin A results
in activation of HDAC6, and this is responsible for tubulin
deacetylation and subsequent microtubule disassembly. We
next assessed whether blockage of HDAC6 by TSA inhibited
the toxin A-induced drop of TER. CaCo-2 cells were treated
withTSA for 1 h prior to exposure of toxinA for 3, andTERwas
measured, starting with an initial value of 300 ohms/cm2. As
shown in Fig. 4G, the drop of TER by toxin A was significantly
inhibited by TSA. The TER in cells treated with TSA alone was
relatively higher than that in cells exposed to control medium.
These results also suggest that the tubulin assembly regulated
by HDAC6 is also strongly associated with barrier function of
epithelial cells.
Microtubule Disorganization in Mouse Epithelium Causes
Gut Inflammation—Given our observations that toxin A
caused tubulin deacetylation and subsequent microtubule
depolymerization and toxin A is known to cause gut inflamma-
tion, we speculated that microtubule disorganization in epithe-
lial cells might result in an inflammatory response with barrier
dysfunction in the gut. To investigate this possibility, we first
tested the effect of colchicine, which inhibits microtubule
polymerization (14), and taxol, a microtubule hyperstabilizer
(15), on microtubule polymerization in human colonocytes. In
HT29 cells, treatment of colchicine (5 M) triggered tubulin
deacetylation (Fig. 5A, top) and caused marked depolymeriza-
tion of microtubules (Fig. 5A, bottom). However, taxol did not
increase deacetylation of tubulin and hyperstabilized the
microtubules in contrast to colchicine (data not shown).
Because changes in microtubule organization triggered loss
of epithelial barrier function as well as cell morphology changes
(35), we next assessed whether colchicine, an inhibitor of
microtubule polymerization, caused barrier dysfunction of
colonic epithelial cells leading to inflammatory response in the
gut. CaCo-2 cells were grown on semipermeable filters and
exposed to colchicine for 8 h, andTERwasmeasured. As shown
in Fig. 5B, colchicine treatment resulted in amarked decrease in
TER, suggesting that microtubule disassembly is strongly asso-
ciated with barrier dysfunction of colonocytes.
We then tested the effect of colchicine in ileal loops of intact
mice. CD1 mice were anesthetized, and PBS or colchicine (5
M) was injected into the lumen of ileal loops. After 4 h, muco-
sal tissue extracts were prepared by scraping the mucosa, and
FIGURE 5.Disorganization ofmicrotubules in epithelial cells and its asso-
ciation with inflammation. A, HT29 cells were treated with medium (con),
DMSO, or colchicine (5M) for 2h, anddeacetylationof tubulinwas examined
(top). Changes in microtubule organization were visualized by immuno-
staining with an antibody against acetylated -tubulin, followed by confocal
microscopy (bottom). The results shown are representative of three inde-
pendent experiments. B, colchicine causes a significant drop in the TER of
CaCo2 cells. The bars represent the mean  S.E. (error bars) of three experi-
ments performed in triplicate; *, p  0.001 versus non-stimulated cells. C–E,
ileal loops of anesthetized CD1 mice (n 8 mice/group) were injected with
PBS or colchicine (1 g of colchicine, 100 l of PBS) for 4 h. C, tissue extracts
obtained from ileal loops were resolved on polyacrylamide gels and probed
with an antibody against acetylated -tubulin. D, mucosal damage was
observed in colchicine-treated mice. Treatment with colchicine was associ-
atedwith abnormally shapedepithelial cells in the ileal tissuesof treatedmice
(arrowheads). E, the concentration of IL-6 was measured from ileal loops
exposed to PBS, colchicine, or toxin A (TxA). The bars represent the mean
S.E. of three independent experiments, eachwith triplicate determinations. *,
p 0.005 versus PBS-treated mice. Error bars, S.E.
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the levels of acetylated tubulin were measured by immunoblot
analysis. Consistent with the results observed in cultured
colonocytes, colchicine-treated mice experienced significant
tubulin deacetylation compared with PBS-treated mice (Fig.
5C). H&E staining of intestinal sections revealed that colchicine
caused marked mucosal damage (Fig. 5D), as evidenced by
abnormally shaped cells and shrinkage of epithelial cell nuclei
in colchicine-treated mice (Fig. 5D, arrowheads). To evaluate
inflammation in the gut, we next measured the mucosal con-
centrations of IL-6, a well characterized proinflammatory cyto-
kine, in toxin A-exposed mouse ileum (36). Colchicine signifi-
cantly increased IL-6 production compared with the PBS
control, and the level was similar to that seen in toxinA-admin-
istrated mouse ileal loops (Fig. 5E). These results suggest that
microtubule disorganization induced by colchicine like toxin A
may trigger gut inflammation and mucosal damage.
TSA-induced Blockage of Tubulin Deacetylation Attenuates
Inflammation and Enterocyte Apoptosis in a Toxin A-induced
Mouse Enteritis Model—Finally, we investigated the possible
inhibitory effect of the HDAC6 inhibitor, TSA, on toxin A-in-
duced mucosal damage and acute gut inflammation in mice.
We first determined the minimal
dose of TSA capable of having a
therapeutic effect on the mouse gut
epithelium without evidence of cel-
lular toxicity. Closed ileal loops of
CD1mice were exposed to different
doses of TSA for 4 h, and the levels
of tubulin deacetylation and TNF-
 expression, a marker of acute
inflammation in toxin A-induced
mouse enteritis (37), weremeasured
from tissue extracts. As shown in
Fig. 6A, treatment with 100 or 1,000
nM TSA increased TNF- and
tubulin acetylation in the mouse
epithelium. In contrast, 10 nM TSA
increased tubulin acetylation but
did not increase TNF- levels.
Therefore, 10 nM TSA was used in
the subsequent experiments. For
those experiments, closed ileal
loops ofCD1micewere treatedwith
PBS (control), TSA alone, toxin A
alone, or TSA plus toxin A for 4 h,
and then the levels of tubulin
deacetylation were measured. As
expected, treatmentwith TSA alone
increased tubulin acetylation com-
pared with the PBS control, and
treatment with toxin A alone
decreased tubulin acetylation com-
paredwith the PBS control (Fig. 6B).
However, the toxin A-induced
tubulin deacetylation was signifi-
cantly blocked byTSAco-treatment
(Fig. 6B). Similarly, toxin A-treated
mice showed increased TNF- and
mucosal damage, but these effects were abolished by TSA co-
treatment (Fig. 6,C andD). Becausewe previously reported that
toxin A-induced colonocyte apoptosis in cultured cells and an
animal colitis model was a critical step in toxin A-induced
mucosal damage and inflammation (32, 33, 36), we measured
caspase-3 activation in tissue extracts. We found that toxin A
increased caspase-3 activation, but this effect was significantly
decreased by TSA co-treatment (Fig. 6E).
DISCUSSION
C. difficile toxinA is known to cause inactivation of Rho fam-
ily proteins, leading to actin disaggregation in cultured cells (7).
Toxin A triggers monoglucosylation of Rho, Rac, and Cdc42 at
threonine 37, rendering these factors unable to participate in
the formation of actin filaments (7, 38–40). Toxin A-treated
cells typically become rounded due to abnormalities in the
cytoskeletal components (2, 41–43). Although this has been
largely attributed to inactivation of Rho family proteins and
subsequent actin disaggregation, we postulated that toxin A
could also affect post-translational modification of tubulin and
microtubule instability. We report here that toxin A treatment
FIGURE 6. TSA-induced HDAC6 inhibition reduces toxin A (TxA)-induced inflammatory responses and
destruction of villi in the mouse ileum. A, to determine a TSA concentration suitable for examination of
cellular responseswithout inflammationormucosal damage,weprepared closed ileal loops in thedistal ilea of
CD1mice (n 5mice/group) and injected themwith different concentrations of TSA in 100l of PBS. Tubulin
deacetylation and TNF- concentrationsweremeasured in the ileal tissues. The bars represent themean S.E.
(n 5mice/group, each with triplicate determinations); *, p 0.005 versus PBS-treatedmice. B–E, mouse ileal
loops were injected with 100 l of PBS alone or PBS containing TSA (10 nM), toxin A (3 g of toxin A, 100 l of
PBS), or toxin A plus TSA. After 4 h, animals were sacrificed, and ileal loops were removed and processed. B,
tissue lysates were resolved on 10% polyacrylamide gels and probed with antibodies against acetylated -tu-
bulin and-actin. The results shownare representative of three separatemouse experiments.C, concentration
of TNF- in the ileal tissues. Data are expressed as mean S.E. (n 5 mice/group, each with triplicate deter-
minations); *, p  0.005 versus toxin A-injected mice. D, light micrographs of mouse ileum (H&E staining;
original magnification,200). E, the extracts from ileal tissues were resolved on 15% polyacrylamide gels and
probed with antibodies against caspase-3 or -actin. Data are representative of three independent samples.
Error bars, S.E.
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of human colonocytes caused tubulin deacetylation and subse-
quent microtubule depolymerization. Moreover, we identified
HDAC6, the only known cytosolic tubulin deacetylase (19), as a
major mediator of toxin A-induced tubulin deacetylation and
subsequent microtubule depolymerization in human colono-
cytes. Post-translational modification of tubulin has been
reported to regulate microtubule formation, which is a major
component of cytoskeletal maintenance and alteration (9–11).
As such, our finding that toxin A induces tubulin deacetylation
in colonocytes provides new insight into the molecular mecha-
nism responsible for the rapid and severe cell rounding seen in
toxin A-treated cells.
The small Rho-GTPase proteins , Rho (44), Rac (45), and
Cdc42 (46), have been reported to regulate microtubule
dynamics in addition to their well characterized roles in form-
ing the actin cytoskeleton. For example, Rac1 regulates micro-
tubule dynamics to promote the formation of stable microtu-
bules in migrating cells (45), and RhoA has been reported to
stabilize microtubules (44). Given that Rho family proteins are
associated with microtubule dynamics, and toxin A has been
shown to inactivate Rho family proteins through glucosylation
at Thr37, we speculated that toxin A-induced tubulin deacety-
lation in colonocytes might be associated with inactivation of
Rho family proteins. Interestingly, UDP-2,3-dialdehyde-in-
duced blockage of toxin A enzymatic activity did not com-
pletely inhibit toxin A-induced tubulin deacetylation (Fig. 3A).
In addition, preincubation of cells with NAC, which scavenges
H2O2, one of the main ROS produced by toxin A treatment of
colonocytes (33) significantly blocked tubulin deacetylation in
toxin A-treated cells (Fig. 3B), whereas exposure of human
colonocytes to H2O2 significantly increased tubulin deacetyla-
tion. Considering that toxin A caused production of H2O2 in
human colonocytes (33), these results suggest that abnormal
tubulin deacetylation in toxin A-treated colonocytes was
mainly dependent on the enzymatic activity of toxin A but may
also involve toxin A-induced signaling molecules, such as
H2O2. Based on the previous report that exposure of hepato-
cytes to H2O2 activated HDAC family proteins (47), H2O2 may
be an essential molecule for activation of HDAC6 in human
colonocytes exposed to toxin A.
Microtubule instability has been shown to increase during
viral infection. For example, internalization of the human
immunodeficiency virus (HIV) is regulated byHDAC6; overex-
pression of active HDAC6 prevents HIV infection through
tubulin deacetylation (48). Therefore, it is conceivable that
microtubule depolymerization and HDAC6 activation in toxin
A-treated human colonocytes may mediate internalization of
toxin A after receptor binding. However, based on our previous
finding that internalization of toxin A in human colonocytes
(NCM460 cells) occurredwithin 5min and that 1-h exposure of
toxin A caused complete glucosylation (inactivation) of Rho
family proteins (28), the tubulin deacetylation noted herein
after 4 h of toxin A exposure is not likely to be associated with
the internalization of toxin A.
In colonic epithelial cells involved in maintaining the barrier
function, cytoskeletal disruption may damage tight junctions
and cause failure of focal contact formation, possibly leading to
large scale exposure of luminal pathogens to immune cells in
lamina propria (32, 36). In this context, toxinA-inducedmicro-
tubule depolymerizationmay function along with actin disrup-
tion to synergistically contribute to cell rounding and mucosal
damage. As shown in Fig. 4, less rounding and better viability
were observed in colonocytes exposed to toxin A plus TSA
compared with cells exposed to toxin A alone, suggesting that
blockage of microtubule depolymerization via TSA-mediated
inhibition of HDAC6 abolished these responses. In our toxin
A-induced mouse enteritis model, blockage of TSA-induced
tubulin deacetylation significantly attenuated toxin A-induced
mucosal damage and TNF- production. Moreover, the in-
creased mucosal cell apoptosis observed in toxin A-treated
mice was substantially reduced in mice co-treated with toxin A
and TSA. Although actin disaggregation has traditionally been
considered the most important outcome of toxin A-induced
Rho protein inactivation (7), our findings indicate that toxin
A-induced tubulin deacetylation is also a critical step for toxin
A-induced cytoskeletal disruption, mucosal damage, and in-
flammation. Our results further suggest three other important
concepts. First, toxin A-induced cytoskeletal disruption in epi-
thelial cellsmay increase the chance of luminal pathogens being
constitutively exposed to the immune system through barrier
dysfunction. Second, HDAC6-mediated tubulin acetylation
and deacetylation appears to be critical for maintenance of
dynamic microtubule instability in the gut epithelium. Third,
toxin A-induced HDAC6 activation causes abnormal tubulin
deacetylation and subsequentmicrotubule depolymerization in
epithelial cells, which in turn is associated with mucosal dam-
age and inflammation in the gut.
We also assessed whether increased instability of microtu-
bules in mouse colonic epithelial cells could cause inflamma-
tory responses and mucosal damage. Colchicine, a well known
inhibitor of microtubule polymerization (14), was used to con-
firm the relationship between cytoskeletal disruption and gut
inflammation. In cultured human colonocytes, colchicine
caused marked microtubule depolymerization. In the mouse
ileal epithelium, colchicine strongly increased tubulin deacety-
lation, IL-6 secretion, and mucosal damage. These results sug-
gest that in gut epithelial cells, microtubule disorganization in
addition to actin disaggregation by toxin A could be a main
trigger of proinflammatory responses. We speculate that this
may be due to the initiation of barrier dysfunction followed by
exposure of immune cells in the lamina propria to luminal bac-
teria and their products, which subsequently triggers severe
inflammation.
In summary, we report that toxin A, in addition to its well
described ability to trigger actin disaggregation, also causes
tubulin deacetylation and microtubule depolymerization in
human colonocytes. This appears to occur through the action
of HDAC6, the only known cytosolic histone deacetylase. The
HDAC6 inhibitor, TSA, inhibits toxin A-induced tubulin de-
acetylation in colonocytes and significantly attenuates proin-
flammatory cytokine production, mucosal damage, and epithe-
lial cell apoptosis in a toxin A-induced mouse enteritis model.
These novel findings provide important new insights into toxin
A-induced cytoskeletal disorganization. In addition, our results
suggest that blocking HDAC6 with TSA may be a potential
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therapeutic approach for ameliorating toxin A-induced acute
inflammation in the gut.
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